Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Photo: Lisa Maree Williams/Getty Images
AstraZeneca's COVID-19 vaccine trial has been put on pause after researchers suspected an adverse reaction in a participant in the United Kingdom, a spokesperson for the company told Stat News.
Why it matters: There are presently nine vaccine candidates in Phase 3 trials. AstraZeneca’s is one of the most promising candidates, and is the first known Phase 3 vaccine trial to be halted.
Of note: It is unclear what the unfavorable reaction was and when it occurred, but the participant is expected to recover. It's also not known who paused the study, how severe or rare the reaction may be and how long the hiatus could last.
- A variety of responses may be flagged for possible adverse reactions, including hospitalization, life-threatening illness and death.
What they're saying: The halt is “a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials," AstraZeneca said in a statement per Stat News.
"In large trials illnesses will happen by chance but must be independently reviewed to check this carefully. We are working to expedite the review of the single event to minimize any potential impact on the trial timeline."
The big picture: AstraZeneca started its Phase 3 trial in the U.S. in late August. The process is taking place across 62 sites throughout the country.
- Phase 2 and 3 trials previously began in the U.K., Brazil and South Africa.